Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder.

@article{Vaughan2009UpdateOA,
  title={Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder.},
  author={Brigette S Vaughan and Joerg M. Fegert and Christopher J. Kratochvil},
  journal={Expert opinion on pharmacotherapy},
  year={2009},
  volume={10 4},
  pages={669-76}
}
BACKGROUND Atomoxetine, an inhibitor of, the presynaptic transporter of norepinephrine, was approved for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents and adults in the USA in 2002, and in Europe, first in the UK and then by mutual recognition in several countries during 2003 and 2004. Since that time, the use of atomoxetine has spread globally and extensive additional research has been conducted evaluating its efficacy and… CONTINUE READING